We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Utilization Patterns of Pulmicort in Real Life Practice

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00660569
First Posted: April 17, 2008
Last Update Posted: December 1, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The purpose of this study is to identify the potential issues during short and mid term utilization of Pulmicort hydro fluoroaklane (HFA) pressurized metered-dose inhaler (pMDI)and describe associated factors.

Condition
Asthma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Utilization Patterns of Pulmicort HFA in Real Life Practice

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Enrollment: 260
Study Start Date: January 2008
Study Completion Date: February 2009
Groups/Cohorts
1
Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion, previously treated with Pulmicort chlorofluorocarbons (CFC) who have changed their treatment to Pulmicort HFA

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Population treated by General Practitioner, Pneumologists or Paediatricians
Criteria

Inclusion Criteria:

  • Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion
  • Patients previously treated with Pulmicort CFC who have changed their treatment to Pulmicort HFA

Exclusion Criteria:

  • Disability that, from investigator point of view, prevent from complying the follow up schedule
  • To have participated in any clinical study in the past 6 months
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00660569


Locations
Spain
Research Site
Sabadell, Barcelona, Spain
Research Site
Alcorcon, Madrid, Spain
Research Site
Leganes, Madrid, Spain
Research Site
San Sebastian de los Reyes, Madrid, Spain
Research Site
Olivares, Sevilla, Spain
Research Site
Fuentes de Ebro, Zaragoza, Spain
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Murcia, Spain
Research Site
Toledo, Spain
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Javier Nuevo Rivero AstraZeneca MC SpainEpidemiologyValue Demonstration Unit
  More Information

Responsible Party: Mónica Tafalla/Medical Science Director, AstraZeneca
ClinicalTrials.gov Identifier: NCT00660569     History of Changes
Other Study ID Numbers: NIS-RES-PUL-2007/1
First Submitted: April 15, 2008
First Posted: April 17, 2008
Last Update Posted: December 1, 2010
Last Verified: November 2010

Keywords provided by AstraZeneca:
asthma treatment
utilization
real life practice

Additional relevant MeSH terms:
Budesonide
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists